Should pharmacists consider albumin levels when administering certain TKIs?

BOSTON – In this video interview, Christy S. Harris, PharmD, BCOP, FHOPA, spoke about the poster sessions presented at the annual meeting of the Association of Hematology/Oncology Pharmacies.

Harris, an associate professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences and clinical pharmacy specialist at the Dana-Farber Cancer Institute, discussed a poster that examined whether albumin level affects the adverse effect profile in patients on tyrosine kinase inhibitors.

“It was really interesting to see,” Harris told Healio.

She also discussed a poster that looked at the best way to give oral sodium bicarbonate when patients are already receiving high-dose methotrexate, especially in the context of the current shortage of intravenous sodium bicarbonate. .

ADD A SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please provide your email address to receive an email when new articles are published on .

” data-action=”subscribe”> Subscribe

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Return to Healio.

Take houses from HOPA